Becton Dickinson announces additional investments in manufacturing

Becton Dickinson (BDX) announced additional investments in its U.S. manufacturing network to add capacity for medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation’s health care system. As part of the company’s 2024 investment of more than $10M to expand manufacturing capacity, new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska. One line is already fully operational with additional lines expected to start up in the coming months. These new lines will boost BD’s capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50%. In addition, BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production. BD also has plans for more than $30M in investments in 2025 to expand manufacturing capacity for IV lines at its plant in Utah to support continued growth in catheter solutions. This follows the company’s 2024 investment of more than $2M for IV line improvements that resulted in increased IV catheter output by more than 40M units annually.